IP Verse

Therapeutic Agent And Therapeutic Method For Pulmonary Hypertension - EP3305321

The patent EP3305321 was granted to Kyowa Hakko Kirin on Oct 16, 2024. The application was originally filed on May 31, 2016 under application number EP16803331A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3305321

KYOWA HAKKO KIRIN
Application Number
EP16803331A
Filing Date
May 31, 2016
Status
Granted And Under Opposition
Sep 13, 2024
Grant Date
Oct 16, 2024
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

J A KEMPJul 16, 2025J A KEMPADMISSIBLE
ALTMANN STOSSEL DICK PATENTANWALTE PARTG MBBJul 15, 2025ALTMANN STOSSEL DICK PATENTANWALTE PARTG MBBADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTJP2002047203
INTERNATIONAL-SEARCH-REPORTJP2014532637
INTERNATIONAL-SEARCH-REPORTJP2016056115
INTERNATIONAL-SEARCH-REPORTWO2005035583
INTERNATIONAL-SEARCH-REPORTWO9710354
OPPOSITIONEP3305321
OPPOSITIONUS2004136996
OPPOSITIONUS2015104447
OPPOSITIONUS8501176
OPPOSITIONWO2008143878
OPPOSITIONWO2013066780
OPPOSITIONWO9847923
SEARCHWO2008143878
SEARCHWO2013066780

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- D8 - https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761070Or ig1s000PharmR.pdf-
OPPOSITION- HITOSHI Y, ET AL., "IN VIVO ADMINISTRATION OF ANTIBODY TO MURINE IL-5 RECEPTOR INHIBITSEOSINOPHILIA OF IL-5 TRANSGENIC MICE", International Immunology, Oxford University Press, GB, GB , (19910101), vol. 03, no. 02, ISSN 0953-8178, pages 135 - 139, XP002942168-
OPPOSITION- MITA S, ET AL., "MOLECULAR CHARACTERIZATION OF THE BETA CHAIN OF THE MURINE INTERLEUKIN 5 RECEPTOR", International Immunology, Oxford University Press, GB, GB , (19910701), vol. 03, no. 07, ISSN 0953-8178, pages 665 - 672, XP000973139-
OPPOSITION- Masashi Ikutani, Shinya Ogawa, Tsutomu Yanagibashi, Terumi Nagai, Kazuki Okada, Yoko Furuichi, Kiyoshi Takatsu, "Elimination of eosinophils using anti-IL-5 receptor alpha antibodies effectively suppresses IL-33-mediated pulmonary arterial hypertrophy", IMMUNOBIOLOGY, Urban und Fischer Verlag, DE, DE , (20180601), vol. 223, no. 6-7, doi:10.1016/j.imbio.2017.12.002, ISSN 0171-2985, pages 486 - 492, XP055532947
OPPOSITION- Kolbeck, R. ; Kozhich, A. ; Koike, M. ; Peng, L. ; Andersson, C.K. ; Damschroder, M.M. ; Reed, J.L. ; Woods, R. ; Dall'Acqua, W.W. ; Stephens, G.L. ; Erjefalt, J.S. ; Bjermer, L. ; Humbles, A.A. ; Gossage, D. ; Wu, H. ; Kiener, P.A. ; Spitalny, G.L. ; Mackay, C.R. ; Molfino, N.A. ; Coyle, A.J., "MEDI-563, a humanized anti-IL-5 receptor @a mAb with enhanced antibody-dependent cell-mediated cytotoxicity function", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20100601), vol. 125, no. 6, doi:10.1016/j.jaci.2010.04.004, ISSN 0091-6749, pages 1344 - 1353.e2, XP027062595
OPPOSITION- Andrea J. Apter;, "Advances in adult asthma diagnosis and treatment and HEDQ in 2010", Journal of Allergy and Clinical Immunology, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL , (20101115), vol. 127, no. 1, doi:10.1016/j.jaci.2010.11.017, ISSN 0091-6749, pages 116 - 122, XP028150394
OPPOSITION- N. A. Molfino; D. Gossage; R. Kolbeck; J. M. Parker; G. P. Geba, "Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor", Clinical & Experimental Allergy, Wiley InterScience, UK, UK , (20110923), vol. 42, no. 5, doi:10.1111/j.1365-2222.2011.03854.x, ISSN 0954-7894, pages 712 - 737, XP071887606
OPPOSITION- M. Weng, Et Al., "Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension", American Journal of Physiology - Lung Cellular and Molecular Physiology, American Physiological Society, US, US , (20111201), vol. 301, no. 6, doi:10.1152/ajplung.00049.2011, ISSN 1040-0605, pages 927 - 936, XP055334294
OPPOSITION- Jacobsen Elizabeth A., Helmers Richard A., Lee James J., Lee Nancy A., "The expanding role(s) of eosinophils in health and disease", Blood, ELSEVIER, AMSTERDAM, NL, AMSTERDAM, NL, (20121101), vol. 120, no. 19, doi:10.1182/blood-2012-06-330845, ISSN 0006-4971, pages 3882 - 3890, XP093300011
OPPOSITION- Barbera J.A, Peinado V.I, Santos S, "Pulmonary hypertension in chronic obstructive pulmonary disease", European Respiratory Journal, European Respiratory Society, (20030501), vol. 21, no. 5, doi:10.1183/09031936.03.00115402, ISSN 0903-1936, pages 892 - 905, XP093300013
OPPOSITION- Dagher Rania, Kumar Varsha, Copenhaver Alan M., Gallagher Sandra, Ghaedi Mahboobe, Boyd Jonathan, Newbold Paul, Humbles Alison A., Kolbeck Roland, "Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity", European Respiratory Journal, European Respiratory Society, (20220301), vol. 59, no. 3, doi:10.1183/13993003.04306-2020, ISSN 0903-1936, page 2004306, XP093300007
OPPOSITION- Ghazi Aasia; Trikha Anita; Calhoun William J, "Benralizumab--a humanized mAb to IL-5R[alpha] with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.", Expert opinion on biological therapy, Informa Healthcare, UK, UK , (20120101), vol. 12, no. 1, doi:10.1517/14712598.2012.642359, ISSN 1744-7682, pages 113 - 118, XP009159038
OPPOSITION- Golay Josée, Taylor Ronald P., "The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs", Antibodies, M D P I AG, CH, CH , (20201001), vol. 9, no. 4, doi:10.3390/antib9040058, ISSN 2073-4468, page 58, XP093300009
SEARCH- HITOSHI Y ET AL, "IN VIVO ADMINISTRATION OF ANTIBODY TO MURINE IL-5 RECEPTOR INHIBITSEOSINOPHILIA OF IL-5 TRANSGENIC MICE", INTERNATIONAL IMMUNOLOGY, OXFORD UNIVERSITY PRESS, (19910101), vol. 3, no. 2, ISSN 0953-8178, pages 135 - 139, XP002942168 [YD] 1-15 * page 138, column 1, line 16 - line 19 *-
SEARCH- MASASHI IKUTANI ET AL, "Elimination of eosinophils using anti-IL-5 receptor alpha antibodies effectively suppresses IL-33-mediated pulmonary arterial hypertrophy", IMMUNOBIOLOGY, DE, (20180601), vol. 223, no. 6-7, doi:10.1016/j.imbio.2017.12.002, ISSN 0171-2985, pages 486 - 492, XP055532947 [T] 1-15
SEARCH- M. WENG ET AL, "Eosinophils are necessary for pulmonary arterial remodeling in a mouse model of eosinophilic inflammation-induced pulmonary hypertension", AMERICAN JOURNAL OF PHYSIOLOGY - LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, US, (20111201), vol. 301, no. 6, doi:10.1152/ajplung.00049.2011, ISSN 1040-0605, pages 927 - 936, XP055334294 [Y] 1-15 * figure 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents